BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

142.90

+3.90

(+2.81%)

As of 01:07PM EDT. Market open.

Loading interactive chart…

Simply Wall St.
With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners
Key Insights Significantly high institutional ownership implies BeiGene's stock price is sensitive to their trading...
Business Wire
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 23, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use.
Simply Wall St.
Shareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past week
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...